Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2021 - 04 - 26 save search
Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
Published: 2021-04-26 (Crawled : 21:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 3.93%
H: 5.77%
C: -0.87%
disease treatment fda fda acceptance kidney syndros
Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate
Published: 2021-04-26 (Crawled : 14:00) - biospace.com/
SCPS | $0.1682
|
|
| O: 1.59%
H: 9.11%
C: 2.6%
fda biopharma drug submission
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
Published: 2021-04-26 (Crawled : 13:15) - biospace.com/
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 12.74%
H: 13.39%
C: 3.32%
huntington disease fda clearance treatment fda gene therapy therapy gene therapies application clearance huntington’s disease
FDA, CDC Decide Benefits of J&J Vaccine Outweigh the Risks
Published: 2021-04-26 (Crawled : 13:15) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.19%
H: 0.12%
C: -0.66%
fda risk vaccine
BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive DisorderShorter Protocol Further Expands Access to Care
Published: 2021-04-26 (Crawled : 13:00) - biospace.com/
BWAY | $4.835 0.94% 0.93% 41K
|
Health Technology
|
| O: 13.29%
H: 5.97%
C: -5.33%
fda clearance treatment fda depression clearance
Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA
Published: 2021-04-26 (Crawled : 13:00) - biospace.com/
ZSAN | $0.5576 7.23% -5.85%
|
Health Technology
|
| O: 7.02%
H: 0.97%
C: 0.97%
fda pharma
BD Announces FDA 510(k) Submission for BD Alaris™ System
Published: 2021-04-26 (Crawled : 11:00) - biospace.com/
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: 0.05%
H: 0.93%
C: 0.57%
fda submission system
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
Published: 2021-04-26 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 10.84%
H: 4.9%
C: 0.14%
new drug treatment fda fda acceptance drug depression major depressive disorder
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.